Fakhry, C., Zhang, Q., Gillison, M. L., Nguyen-Tân, P. F., Rosenthal, D. I., Weber, R. S., . . . Le, Q. (2019). Validation of NRG Oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer (OPC); implications for risk-based therapeutic intensity trials. Cancer.
Chicago-stil citatFakhry, Carole, et al. "Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-positive and HPV-negative Oropharyngeal Squamous Cell Cancer (OPC); Implications for Risk-based Therapeutic Intensity Trials." Cancer 2019.
MLA-referensFakhry, Carole, et al. "Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-positive and HPV-negative Oropharyngeal Squamous Cell Cancer (OPC); Implications for Risk-based Therapeutic Intensity Trials." Cancer 2019.